Insulin resistance improving agent

Abstract

The invention provides an insulin resistance improving agent which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a therapeutic agent for type 2 diabetes, which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention reverses insulin resistance induced from a high fat diet and associated with obesity, and therefore, enables treatment of type 2 diabetes, which is the most common among other types of diabetes.

1 . An insulin resistance improving agent containing, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin.  
     
     
         2 . An insulin resistance improving agent containing, as active components, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin, and leptin or a gene for leptin.  
     
     
         3 . A therapeutic agent for type 2 diabetes containing, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin.  
     
     
         4 . A therapeutic agent for type 2 diabetes containing, as active components, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin, and leptin or a gene for leptin.